Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Goodscend Pharmaceutical Science & Technology is a clinical-stage biopharmaceutical company headquartered in Guangzhou, China, dedicated to the development of advanced inhalation therapies. The company leverages its proprietary technology platforms in dry powder inhalers (DPI), soft mist inhalers (SMI), and nebulized formulations to treat respiratory and systemic diseases. Its pipeline includes high-entry-barrier generic and innovative drugs targeting conditions such as asthma, chronic obstructive pulmonary disease (COPD), and pulmonary arterial hypertension. Goodscend integrates formulation development with device design to ensure precise pulmonary delivery and improved patient outcomes. Led by a team of industry veterans, the company has secured significant venture capital funding to advance its clinical programs toward commercialization.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Goodscend Pharm. Sci. & Tech..